Collaborations in psychedelic drug research have spiked in recent years, with a 500% increase in 2023. This is due to evolving regulatory landscapes and positive outcomes from clinical trials. Explore this shifting environment further ⬇️ bit.ly/3uWuTO0

From the entire team at Algernon, we wish you and your loved ones a wonderful Holiday Season! ☃️

✨ Happy New Year! ✨ Algernon would like to thank you for being part of the journey this year. We look forward to even more success in 2024.

Algernon is delighted to share we have been issued a patent through the US Patent and Trademark Office (USPTO) for the treatment of fatty liver disease (NAFLD), including steatohepatitis (NASH), and NASH-derived hepatocellular carcinoma. For More - bit.ly/3vn5MnJ

We are delighted to have been issued a patent through the United States Patent and Trademark Office (USPTO) for the treatment of three diseases with its drug repirinast. Here is what our CEO has to say about this great development! bit.ly/3vn5MnJ

Traumatic brain injuries and strokes are significant global causes of disability and psychedelics now hold promise in enhancing neurobehavioral outcomes. Algernon is committed to advancing psychedelic DMT for individuals with stroke and TBI. For more ➡️ go.nature.com/3NPMduC

Algernon is pleased to announce the receipt of a notice of allowance from the Japanese Patent Office titled: 'Compositions & Methods for Treating Idiopathic Pulmonary Fibrosis (IPF).' IPF is a serious & fatal lung disease that needs new treatment options - bit.ly/3tXUQws

NEWS RELEASE: We are pleased to report that Algernon has received a notice of intention to grant from the Chinese Patent Office for its anti-fibrotic drug candidate NP-251 (Repirinast). Check out the full press release 👉 bit.ly/3OlZMSX

AI and ML are transforming pharmaceutical research, improving drug discovery, repurposing and clinical testing. Algernon focuses on the drug repurposing model to provide a cost-effective way to discover new uses for drugs. Learn more ➡️ bit.ly/422bnfH

#DrugRepurposingFacts: Ifenprodil is a targeted NMDA receptor antagonist, specifically focusing on the GluN2B receptor. 🧬Algernon has been granted a notice of allowance for the patent application aimed at treating IPF with Ifenprodil. Read more here ➡️ bit.ly/3tXUQws

We are pleased to announce the receipt of a notice of allowance from the Japanese Patent Office titled: 'Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF).' Check out what our CEO says about this great development ➡️ bit.ly/3tXUQws

After many years, the FDA's draft guidance is now illuminating the field of psychedelic research. The FDA released a draft guidance to help researchers in exploring the therapeutic potential of psychedelic drugs for medical conditions. Learn more here ⬇️ bit.ly/3OIOEj3

#DrugRepurposingFacts: Repirinast, Algernon’s top candidate for treating Chronic Kidney Disease (CKD), has shown promising results with a 51% reduction in fibrosis and complementary effects alongside telmisartan. Learn more here! bit.ly/49uM3Bf

The emergence of the psychedelic ibogaine, shows promise in treating chronic disability following TBI. In a study of 30 male US military veterans with TBI, 83% saw improvements in mental health, processing speed working memory. Read more ⬇️ bit.ly/4bE3cdR

Chronic cough is a persistent condition that can last for several weeks for children and adults. Learn more on how NP-120 (Ifenprodil) could help in the treatment for Chronic cough ➡️ bit.ly/3qV6I0L

💊What are the benefits of repurposing drugs? From Alzheimer's to multiple sclerosis, and various rare diseases, several drugs have been discovered and repurposed for their treatment. Learn more here ➡️ bit.ly/49y7CkR

🔬AI's Impact on Drug Discovery Advanced machine learning is transforming traditional drug discovery. By analyzing biological and clinical data, it predicts drug interactions, adverse effects, and uncovers repurposing opportunities. Read more here! bit.ly/3HSexci

We were pleased to receive the latest notice of intention to grant from the Chinese Patent Office for the patent application for its antifibrotic drug candidate NP-251 (Repirinast). Check out what our CEO says about this great development ➡️ bit.ly/49uM3Bf

The Australian Therapeutic Goods Administration (TGA) has launched a Medicines Repurposing Program (MRP) to broaden treatment options. This initiative is dedicating $10.1M for repurposing efforts over four years. Read more on this great initiative! ⬇️ bit.ly/3TMSGtH

Chronic Kidney Disease (CKD) is when the kidneys are damaged or cannot filter blood as well as healthy kidneys, often due to fibrosis. Here is how NP-251 (Repirinast) can help treat this disease ➡️ bit.ly/49x1ZTU